Multiple Myeloma

Pneumococcal Vaccination Induces Antibody Responses in Patients With Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date June 10, 2019

A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.

Treatment With Daratumumab for Multiple Myeloma May Improve Quality of Life

By

Sonali Gattani

Publish Date June 6, 2019

Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.

Subcutaneous Daratumumab Associated With Higher Patient Satisfaction, Drastically Fewer Infusion Reactions Than Intravenous Formulations

By

Susan Moench, PhD, PA-C

Publish Date June 3, 2019

The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.

Once-Weekly Carfilzomib Is Tolerable in Patients With Relapsed/Refractory Multiple Myeloma

By

Sonali Gattani

Publish Date June 3, 2019

Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.

Carfilzomib for Relapsed and Refractory Multiple Myeloma

Publish Date May 31, 2019

[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.